Los Angeles, CA106 Active Studies

Pulmonary Hypertension Clinical Trials in Los Angeles, CA

Find 106 actively recruiting pulmonary hypertension clinical trials in Los Angeles, CA. Connect with local research sites and explore new treatment options.

106
Active Trials
73
Sponsors
37,717
Enrolling

Recruiting Pulmonary Hypertension Studies in Los Angeles

About Pulmonary Hypertension Clinical Trials in Los Angeles

Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.

There are currently 106 pulmonary hypertension clinical trials recruiting participants in Los Angeles, CA. These studies are seeking a combined 37,717 participants. Research is being sponsored by National Cancer Institute LAO, University of Colorado, Denver, Vertex Pharmaceuticals Incorporated and 70 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Hypertension Clinical Trials in Los Angeles — FAQ

Are there pulmonary hypertension clinical trials in Los Angeles?

Yes, there are 106 pulmonary hypertension clinical trials currently recruiting in Los Angeles, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Los Angeles?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Los Angeles research site will contact you about next steps.

Are clinical trials in Los Angeles free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Los Angeles studies also compensate for your time and travel.

What pulmonary hypertension treatments are being tested?

The 106 active trials in Los Angeles are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.

Data updated July 16, 2026 from ClinicalTrials.gov